Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
butylscopolamine + metamizole sodium
- Development stage
- Unknown
- Lead developer
- Quimica Son's
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous, Oral
01
Overview
Busconet is a fixed-dose combination of the antispasmodic butylscopolamine (also known as hyoscine butylbromide) and the non-opioid analgesic metamizole sodium (dipyrone). Developed and marketed by Quimica Son's in Mexico, Busconet is indicated for the treatment of acute, severe spasmodic pain of the gastrointestinal, biliary, and genitourinary tracts, including renal colic, biliary colic, and severe abdominal cramps. Butylscopolamine acts as a competitive antagonist at muscarinic acetylcholine receptors on smooth muscle, leading to muscle relaxation and spasm relief. Metamizole sodium acts as a potent analgesic and antipyretic, primarily by inhibiting prostaglandin synthesis in the central nervous system.
- Brand names
- Biomesina CompuestaBuscapina CompositumBusconet
- Other names
- butilhioscina + metamizol sódicobutylscopolamine + metamizole sodiumbutylscopolamine bromide + metamizole sodiumhyoscine butylbromide + metamizole sodiumscopolamine butylbromide + metamizole sodium
02
Targets
KATP channel (ATP-sensitive potassium channel)CNR1 (Cannabinoid receptor 1)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)mAChR (Muscarinic acetylcholine receptors)Nicotinic Acetylcholine ReceptorTRPA1 (Transient receptor potential cation channel subfamily A member 1)
Beyond the preview
Go deeper on butylscopolamine + metamizole sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on butylscopolamine + metamizole sodium.